Summary
β-Blockers are completely and rapidly absorbed from the gastro-intestinal tract. In their first passage through the liver they are metabolised to a varying extent-the so-called firstpass effect. For propranolol and alprenolol this degradation is partly compensated for by the formation of active metabolites, the 4-OH derivatives.
The β-blocking effect is linearly correlated with the log plasma concentration of the drugs. Although there is also a relationship between the antihypertensive effect of the drugs and their log plasma concentration, it seems to be of limited value to determine the plasma levels of the drugs in order to adjust the therapeutic dose. This is due to the great interindividual differences of the plasma concentration-antihypertensive effect relationship.
It is essential to investigate whether pharmacologically active metabolites are formed. These may not only influence the relationship between plasma concentration and therapeutic effect but may also modify the pharmacological profile of the drug. The plasma levels, and thereby the effects of the drugs, can be modified by other drugs and diseases. Thus practolol, which is mainly eliminated via the kidneys, has a longer plasma half-life in patients with renal failure. The plasma half-life of propranolol, which is eliminated from the body by bio-transformation in the liver, is not prolonged in patients with renal failure, but its metabolites are excreted at a lower rate in such patients.
Although mostβ-blockers have a relatively short plasma half-life (2 to 5 hours), the drugs can be administered twice daily in clinical practice. This is due to the fact that the effect declines according to zero-order kinetics while the elimination of the drug follows first-order kinetics.
It is desirable that all these factors are clarified before a drug is used in clinical practice as they all will have an influence on its dose regimen. The responsibility for this must be on the drug company, which must be able to inform physicians not only about the standard dosage of the drug but also how other drugs and diseases can change the individual responses to the drug.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ablad, B.; Borg, K-O.; Johnsson, G.; Regårdh, C-G and Sölvell, L.: Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxyalprenolol in man. life Sciences 14: 693–704 (1974).
Anavekar, S.N.; Louis, W.J.; Morgan, T.O.; Doyle, A.E.; and Johnston, C.I.: The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma nor adrenaline levels. Clinical and experimental Pharmacology and Physiology 2: 203–212 (1975).
Bodem, G. and Chidsey, CA.: Pharmacokinetic studies of practolol, a beta-adrenergic antagonist in man. Clinical Pharmacology and Therapeutics 14: 26–29 (1973).
Bodem, G.; Grieser, H.; Eichelbaum, M. and Gugler, R.: Pharmacokinetics of practolol in renal failure. European Journal of Clinical Pharmacology 7: 249–252 (1974).
Borg, K-O.; Carlsson, E.; Hoffmann, K-J.; Jönsson, T-E., Thorin, H. and Wallin, B.; Metabolism of metoprolol(3 H) in man, the dog and the rat. Acta Pharmacologica et Toxicologica 36 (Suppl. 5): 125–135 (1975).
Branch, R.A.; Shand, D.G. and Nies, A.S.: Hemodynamic drug interactions: The reduction of oxyphenbutazone clearance by dl-propranolol in the dog. Journal of Pharmacology and Experimental Therapeutics 187: 133–137 (1973a).
Branch, R.A.; Shand, D.G.; Wilkinson, G.R. and Nies, A.S.: The reduction of lidocaine clearance by dl-propranolol: An example of hemodynamic drug interaction. Journal of Pharmacology and Experimental Therapeutics 184: 515–519 (1973b).
Branch, R.A.; James, J. and Read, A.E.: The pharmacokinetics of (+)-propranolol in normal subjects and patients with chronic liver disease. British Journal of Clinical Pharmacology 2: 183–184 (1975).
Collste, P.; Frisk-Holmberg, M.; Haglund, K.; Orme, M. and Rawlins, M.: Plasma levels and effects of metoprolol in hypertensive patients. Abstract from Sixth International Congress of Pharmacology, Helsinki (1975).
Coltart, DJ.; and Shand, D.G.: Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. British Medical Journal 3: 731–734 (1970).
Eastwood, J.B.; Curtis, J.R. and Smith, R.B.: Pharmacodynamics of practolol in chronic renal failure. British Medical Journal 4: 320–322 (1973).
Edvardsson, N.; Fritz, H.; Hällén, J. and Rasmussen, A.: Relationship between effect and plasma levels of metoprolol in essential hypertension (In preparation, 1976).
Ekelund, L.G.; Johnsson, G.; Melcher, A. and Orö, L.: Effects of cedilanid-D in combination with metoprolol on exercise tolerance and systolic time intervals in angina pectoris. American Journal of Cardiology (In press, 1976).
George, CF.; Fenyvesi, T.; Conolly, M.E. and Dollery, CT.: Pharmacokinetics of dextro-, laevo- and racemic propranolol in man. European Journal of Clinical Pharmacology 4: 74–76 (1972).
Hansson, L.; Zweifler, A.J.; Julius, S. and Ellis, C.N.: Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response. International Journal of Clinical Pharmacology 10: 79–89 (1974).
Johnsson, G.G. and Regårdh, C-G.: Lack of biological interaction of alprenolol and salicylate in man. European Journal of Clinical Pharmacology 6: 9–14 (1973).
Johnsson, G.; Regårdh, C-G. and Sölvell, L.: Combined pharmacokinetics G.; Re0gardh, C-G. and Sölvell, L.: Combined pharmacokinetic antagonist metoprolol. Acta Pharmacologica et Toxicologica 36 (Suppl. 5): 31–44 (1975).
Lowenthal, D.T.; Briggs, W.A.; Gibson, T.P.; Nelson, H. and Cirksena, W.J.: Pharmacokinetics of oral propranolol in chronic renal disease. Clinical Pharmacology and Therapeutics 16: 761 (1974).
Ohnhaus, E.E.; Niiesch, E.; Meier, J. and Kalberer, F.: Pharmacokinetics of unlabelled and C-labelled pin-dolol in uraemia. European Journal of Clinical Pharmacology 7: 25–29 (1974).
Orme, M.; Collste, P.; Haglund, K.; Frisk-Holmberg, M. and Rawlins, M.: Plasma levels and effects of alprenol in hypertensive patients. Abstract from Sixth International Congress of Pharmacology, Helsinki (1975).
Peters, M.A.: Possible mechanism(s) of alprenolol (beta adrenergic receptor blocking agent) prolongation of pentobarbital hypnosis in mice. Journal of Pharmacology and Experimental Therapeutics 181: 417–424 (1972).
Regårdh, C-G.: Pharmacokinetics and biopharmaceutics of some adrenergic β-receptor antagonists with special emphasis on alprenolol beta-receptor antagonists with special emphasis on alprenolol Acta Pharmacologica et Toxicologica, Vol. 37 (1975).
Regårdh, C-G., Johnsson, G., Jördo, L. and Sölvell, L. Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses. Acta Pharmacologica et Toxicologica 36 (Suppl. 5): 45–58 (1975).
Thompson, F.D.; Joekes, A.M. and Foulkes, D.M.: Pharmacodynamics of propranolol in renal failure. British Medical Journal 2: 434–436 (1972).
Zacest, R. and Koch-Weser, J.: Relation of propranolol plasma level to β-blockade during oral therapy. Pharmacology 7: 178–184 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johnsson, G., Regårdh, C.G. Clinical Pharmacokinetics ofβ-Adrenoreceptor Blockers. Drugs 11 (Suppl 1), 111–121 (1976). https://doi.org/10.2165/00003495-197600111-00026
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-197600111-00026